BR112023018078A2 - Molécula híbrida compreendendo um fragmento fc de anticorpo e pelo menos um peptídeo citrulinado derivado de fibrina e usos da mesma - Google Patents
Molécula híbrida compreendendo um fragmento fc de anticorpo e pelo menos um peptídeo citrulinado derivado de fibrina e usos da mesmaInfo
- Publication number
- BR112023018078A2 BR112023018078A2 BR112023018078A BR112023018078A BR112023018078A2 BR 112023018078 A2 BR112023018078 A2 BR 112023018078A2 BR 112023018078 A BR112023018078 A BR 112023018078A BR 112023018078 A BR112023018078 A BR 112023018078A BR 112023018078 A2 BR112023018078 A2 BR 112023018078A2
- Authority
- BR
- Brazil
- Prior art keywords
- fibrin
- antibody
- derived
- fragment
- hybrid molecule
- Prior art date
Links
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 title abstract 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000009123 Fibrin Human genes 0.000 abstract 2
- 108010073385 Fibrin Proteins 0.000 abstract 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 2
- 229950003499 fibrin Drugs 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
molécula híbrida compreendendo um fragmento fc de anticorpo e pelo menos um peptídeo citrulinado derivado de fibrina e usos da mesma. a invenção refere-se a uma molécula híbrida compreendendo pelo menos um fragmento fc de anticorpo covalentemente ligado a pelo menos um peptídeo derivado de fibrina compreendendo pelo menos um resíduo citrulil, aos usos de tal molécula híbrida e seu processo de produção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2102803A FR3120865A1 (fr) | 2021-03-19 | 2021-03-19 | Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations |
| PCT/FR2022/050504 WO2022195237A1 (fr) | 2021-03-19 | 2022-03-18 | Molécule hybride comprenant un fragment fc d'anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018078A2 true BR112023018078A2 (pt) | 2023-10-03 |
Family
ID=78332816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018078A BR112023018078A2 (pt) | 2021-03-19 | 2022-03-18 | Molécula híbrida compreendendo um fragmento fc de anticorpo e pelo menos um peptídeo citrulinado derivado de fibrina e usos da mesma |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4308715A1 (pt) |
| JP (1) | JP2024515014A (pt) |
| CN (1) | CN117043349A (pt) |
| AU (1) | AU2022237943A1 (pt) |
| BR (1) | BR112023018078A2 (pt) |
| CA (1) | CA3209694A1 (pt) |
| FR (1) | FR3120865A1 (pt) |
| IL (1) | IL305831A (pt) |
| WO (1) | WO2022195237A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| ES2659517T3 (es) * | 2007-05-30 | 2018-03-16 | Xencor, Inc. | Métodos y composiciones para inhibir células que expresan CD32B |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| ES2947566T3 (es) | 2013-12-23 | 2023-08-11 | Covalab | Sustratos de Mtg para la conjugación covalente de compuestos |
| CA3014443A1 (en) | 2016-02-12 | 2017-08-17 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
-
2021
- 2021-03-19 FR FR2102803A patent/FR3120865A1/fr active Pending
-
2022
- 2022-03-18 EP EP22715347.5A patent/EP4308715A1/fr active Pending
- 2022-03-18 CA CA3209694A patent/CA3209694A1/en active Pending
- 2022-03-18 BR BR112023018078A patent/BR112023018078A2/pt unknown
- 2022-03-18 JP JP2023555853A patent/JP2024515014A/ja active Pending
- 2022-03-18 WO PCT/FR2022/050504 patent/WO2022195237A1/fr active Application Filing
- 2022-03-18 AU AU2022237943A patent/AU2022237943A1/en active Pending
- 2022-03-18 CN CN202280022455.6A patent/CN117043349A/zh active Pending
- 2022-03-18 IL IL305831A patent/IL305831A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4308715A1 (fr) | 2024-01-24 |
| JP2024515014A (ja) | 2024-04-04 |
| CN117043349A (zh) | 2023-11-10 |
| CA3209694A1 (en) | 2022-09-22 |
| WO2022195237A1 (fr) | 2022-09-22 |
| AU2022237943A1 (en) | 2023-09-07 |
| IL305831A (en) | 2023-11-01 |
| FR3120865A1 (fr) | 2022-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900003A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| BR112019005316A2 (pt) | anticorpos monoclonais para morte programada 1 (pd-1) | |
| ECSP23053070A (es) | Anticuerpos multiespecíficos con especificidad para il-4r e il-31 | |
| PE20230348A1 (es) | Variantes de anticuerpos felinos | |
| BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
| CL2019002894A1 (es) | Anticuerpo monoclonal para pd-l1. | |
| CL2022003390A1 (es) | Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2. | |
| BR112023018078A2 (pt) | Molécula híbrida compreendendo um fragmento fc de anticorpo e pelo menos um peptídeo citrulinado derivado de fibrina e usos da mesma | |
| BR112022000628A2 (pt) | Anticorpos anti-tigit e aplicação dos mesmos | |
| BR112018068755A2 (pt) | aditivos de barreira | |
| EA201691834A1 (ru) | Новый способ очистки гонадотропина | |
| CO2024004055A2 (es) | Polipéptidos | |
| CO2022007332A2 (es) | Polímero de biomolécula multimérico, multiespecífico y multifuncional que tiene una duración in vivo prolongada | |
| PE20180490A1 (es) | Moleculas de fusion | |
| PE20180498A1 (es) | Inmunoglobulinas conjugadas en cys80 | |
| BR112022012221A2 (pt) | Composições de enterovírus purificadas e métodos de purificação com cromatografia de afinidade por glutationa | |
| BR112022013575A2 (pt) | Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos | |
| CO2018010286A2 (es) | Método para la purificación de proteínas | |
| AR125450A1 (es) | Anticuerpos anti-adgre2 y usos de los mismos | |
| BR112023000482A2 (pt) | Anticorpos antibetacelulina, fragmentos dos mesmos e moléculas de ligação multiespecíficas | |
| AR116937A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| AR122969A1 (es) | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas | |
| AR125451A1 (es) | Anticuerpos anti-clec12a y usos de los mismos | |
| UY39687A (es) | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo | |
| AR122286A1 (es) | Anticuerpos potenciadores del factor h y usos de estos |